![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/11/2896628/0/en/Pharvaris-Announces-Annual-Meeting-of-Shareholders.html
https://www.globenewswire.com/news-release/2024/06/04/2892897/0/en/Pharvaris-Highlights-Properties-of-Deucrictibant-in-Data-Presentations-at-Recent-Congresses.html
https://www.globenewswire.com/news-release/2024/05/13/2880240/0/en/Pharvaris-to-Present-Clinical-and-Nonclinical-Data-at-Upcoming-Congresses.html
https://www.globenewswire.com/news-release/2024/05/08/2878257/0/en/Pharvaris-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/04/10/2861110/0/en/Pharvaris-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/04/10/2861109/0/en/Pharvaris-Appoints-David-Nassif-J-D-as-Chief-Financial-Officer.html
https://www.globenewswire.com/news-release/2024/04/04/2857613/0/en/Pharvaris-to-Present-Deucrictibant-Clinical-Data-at-the-CIIC-Spring-2024-Conference.html
https://www.globenewswire.com/news-release/2024/03/18/2847642/0/en/Pharvaris-Announces-Phase-3-Clinical-Study-Design-for-Recently-Initiated-RAPIDe-3-Study-and-Presents-Quality-of-Life-Improvement-and-Caregiver-Behavior-Data-at-Two-Recent-HAE-Congr.html
https://www.globenewswire.com//news-release/2024/03/06/2841228/0/en/Pharvaris-to-Present-Deucrictibant-Clinical-Data-at-Upcoming-Congresses.html
https://www.globenewswire.com//news-release/2024/03/05/2840256/0/en/Pharvaris-to-Participate-in-the-Leerink-Global-Biopharma-Conference-2024.html